Cargando…
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283476/ https://www.ncbi.nlm.nih.gov/pubmed/22260418 http://dx.doi.org/10.1186/1742-2094-9-14 |
_version_ | 1782224193055621120 |
---|---|
author | Jarius, Sven Ruprecht, Klemens Wildemann, Brigitte Kuempfel, Tania Ringelstein, Marius Geis, Christian Kleiter, Ingo Kleinschnitz, Christoph Berthele, Achim Brettschneider, Johannes Hellwig, Kerstin Hemmer, Bernhard Linker, Ralf A Lauda, Florian Mayer, Christoph A Tumani, Hayrettin Melms, Arthur Trebst, Corinna Stangel, Martin Marziniak, Martin Hoffmann, Frank Schippling, Sven Faiss, Jürgen H Neuhaus, Oliver Ettrich, Barbara Zentner, Christian Guthke, Kersten Hofstadt-van Oy, Ulrich Reuss, Reinhard Pellkofer, Hannah Ziemann, Ulf Kern, Peter Wandinger, Klaus P Bergh, Florian Then Boettcher, Tobias Langel, Stefan Liebetrau, Martin Rommer, Paulus S Niehaus, Sabine Münch, Christoph Winkelmann, Alexander Zettl U, Uwe K Metz, Imke Veauthier, Christian Sieb, Jörn P Wilke, Christian Hartung, Hans P Aktas, Orhan Paul, Friedemann |
author_facet | Jarius, Sven Ruprecht, Klemens Wildemann, Brigitte Kuempfel, Tania Ringelstein, Marius Geis, Christian Kleiter, Ingo Kleinschnitz, Christoph Berthele, Achim Brettschneider, Johannes Hellwig, Kerstin Hemmer, Bernhard Linker, Ralf A Lauda, Florian Mayer, Christoph A Tumani, Hayrettin Melms, Arthur Trebst, Corinna Stangel, Martin Marziniak, Martin Hoffmann, Frank Schippling, Sven Faiss, Jürgen H Neuhaus, Oliver Ettrich, Barbara Zentner, Christian Guthke, Kersten Hofstadt-van Oy, Ulrich Reuss, Reinhard Pellkofer, Hannah Ziemann, Ulf Kern, Peter Wandinger, Klaus P Bergh, Florian Then Boettcher, Tobias Langel, Stefan Liebetrau, Martin Rommer, Paulus S Niehaus, Sabine Münch, Christoph Winkelmann, Alexander Zettl U, Uwe K Metz, Imke Veauthier, Christian Sieb, Jörn P Wilke, Christian Hartung, Hans P Aktas, Orhan Paul, Friedemann |
author_sort | Jarius, Sven |
collection | PubMed |
description | BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. METHODS: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). RESULTS: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. CONCLUSION: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients. |
format | Online Article Text |
id | pubmed-3283476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32834762012-02-22 Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients Jarius, Sven Ruprecht, Klemens Wildemann, Brigitte Kuempfel, Tania Ringelstein, Marius Geis, Christian Kleiter, Ingo Kleinschnitz, Christoph Berthele, Achim Brettschneider, Johannes Hellwig, Kerstin Hemmer, Bernhard Linker, Ralf A Lauda, Florian Mayer, Christoph A Tumani, Hayrettin Melms, Arthur Trebst, Corinna Stangel, Martin Marziniak, Martin Hoffmann, Frank Schippling, Sven Faiss, Jürgen H Neuhaus, Oliver Ettrich, Barbara Zentner, Christian Guthke, Kersten Hofstadt-van Oy, Ulrich Reuss, Reinhard Pellkofer, Hannah Ziemann, Ulf Kern, Peter Wandinger, Klaus P Bergh, Florian Then Boettcher, Tobias Langel, Stefan Liebetrau, Martin Rommer, Paulus S Niehaus, Sabine Münch, Christoph Winkelmann, Alexander Zettl U, Uwe K Metz, Imke Veauthier, Christian Sieb, Jörn P Wilke, Christian Hartung, Hans P Aktas, Orhan Paul, Friedemann J Neuroinflammation Research BACKGROUND: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. OBJECTIVE: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. METHODS: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). RESULTS: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. CONCLUSION: This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients. BioMed Central 2012-01-19 /pmc/articles/PMC3283476/ /pubmed/22260418 http://dx.doi.org/10.1186/1742-2094-9-14 Text en Copyright ©2012 Jarius et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Jarius, Sven Ruprecht, Klemens Wildemann, Brigitte Kuempfel, Tania Ringelstein, Marius Geis, Christian Kleiter, Ingo Kleinschnitz, Christoph Berthele, Achim Brettschneider, Johannes Hellwig, Kerstin Hemmer, Bernhard Linker, Ralf A Lauda, Florian Mayer, Christoph A Tumani, Hayrettin Melms, Arthur Trebst, Corinna Stangel, Martin Marziniak, Martin Hoffmann, Frank Schippling, Sven Faiss, Jürgen H Neuhaus, Oliver Ettrich, Barbara Zentner, Christian Guthke, Kersten Hofstadt-van Oy, Ulrich Reuss, Reinhard Pellkofer, Hannah Ziemann, Ulf Kern, Peter Wandinger, Klaus P Bergh, Florian Then Boettcher, Tobias Langel, Stefan Liebetrau, Martin Rommer, Paulus S Niehaus, Sabine Münch, Christoph Winkelmann, Alexander Zettl U, Uwe K Metz, Imke Veauthier, Christian Sieb, Jörn P Wilke, Christian Hartung, Hans P Aktas, Orhan Paul, Friedemann Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title_full | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title_fullStr | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title_full_unstemmed | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title_short | Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients |
title_sort | contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283476/ https://www.ncbi.nlm.nih.gov/pubmed/22260418 http://dx.doi.org/10.1186/1742-2094-9-14 |
work_keys_str_mv | AT jariussven contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT ruprechtklemens contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT wildemannbrigitte contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT kuempfeltania contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT ringelsteinmarius contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT geischristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT kleiteringo contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT kleinschnitzchristoph contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT bertheleachim contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT brettschneiderjohannes contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT hellwigkerstin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT hemmerbernhard contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT linkerralfa contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT laudaflorian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT mayerchristopha contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT tumanihayrettin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT melmsarthur contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT trebstcorinna contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT stangelmartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT marziniakmartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT hoffmannfrank contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT schipplingsven contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT faissjurgenh contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT neuhausoliver contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT ettrichbarbara contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT zentnerchristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT guthkekersten contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT hofstadtvanoyulrich contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT reussreinhard contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT pellkoferhannah contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT ziemannulf contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT kernpeter contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT wandingerklausp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT berghflorianthen contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT boettchertobias contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT langelstefan contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT liebetraumartin contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT rommerpauluss contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT niehaussabine contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT munchchristoph contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT winkelmannalexander contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT zettluuwek contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT metzimke contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT veauthierchristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT siebjornp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT wilkechristian contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT hartunghansp contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT aktasorhan contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients AT paulfriedemann contrastingdiseasepatternsinseropositiveandseronegativeneuromyelitisopticaamulticentrestudyof175patients |